Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains
NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.
Pharma & Biotech
Pharma & Biotech
Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?
NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.
Pharma & Biotech
ImmunityBio resubmits FDA application for ANKTIVA in bladder cancer after agency requests updated efficacy data
ImmunityBio has resubmitted its supplemental biologics license application to the U.S. Food and Drug Administration for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, after the agency requested updated long-term efficacy data in March 2026. The resubmission follows a regulatory exchange that began in January
Pharma & Biotech
Johnson & Johnson strengthens its multiple myeloma franchise with TECVAYLI and DARZALEX FASPRO approval. What clinicians are watching next
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.
Pharma & Biotech
Can Sciwind Biosciences’ ecnoglutide challenge conventional GLP-1 drugs in the expanding obesity market?
China approves Sciwind Biosciences’ ecnoglutide for weight management. Discover what the biased GLP-1 mechanism could change in the obesity drug race.
Pharma & Biotech
Insilico Medicine’s AI-designed anemia therapy begins Phase I testing in collaboration with TaiGen
Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.
Medical Devices & Diagnostics
CE Mark clearance for BD Revello stent highlights growing competition in endovascular PAD therapies
BD secures EU CE Mark for the Revello vascular covered stent for iliac artery disease. Explore what this device could change for PAD treatment in Europe.
Medical Devices & Diagnostics
Can ECG-based monitoring reshape virtual GI care models? Lohman Technologies and Salvo Health deepen alliance
Lohman Technologies and Salvo Health expand their partnership to deploy HomECG+ monitoring in GI care. Discover why HRV data may reshape digital chronic care.
Pharma & Biotech
Why Servier’s $2.5bn acquisition of Day One Biopharmaceuticals could reshape the pediatric glioma treatment landscape
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.
Pharma & Biotech
Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe
CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.